Patrys has raised A$3.2 million through a share placement to fund its injectable quetiapine program’s Phase 1A clinical trial and FDA pre-IND preparations.
- Placement raised approximately A$3.2 million at A$0.024 per share
- Funds earmarked for Phase 1A clinical trial and manufacturing readiness
- Directors to participate subject to shareholder approval
- Placement includes attaching unlisted options exercisable at A$0.048
- Strengthens balance sheet amid advancing delirium treatment program
Capital Raise Targets Clinical Milestones
Clinical-stage biotech Patrys (ASX:PAB) has successfully raised about A$3.2 million through a placement of roughly 133 million shares priced at A$0.024 each. The raise, which attracted strong demand from both new and existing strategic investors, is designed to bolster the company’s balance sheet and finance the next critical steps in its injectable quetiapine program targeting delirium treatment.
CEO Dr Samantha South highlighted the significance of the placement in a challenging market, noting it positions Patrys to execute a Phase 1A clinical trial, a prerequisite for their pre-IND filing with the US FDA. This trial represents a pivotal step toward regulatory approval and eventual commercialisation.
Clinical and Regulatory Progression
The funds will support several near-term objectives including advancing the Phase 1A first-in-human trial, preparing manufacturing processes to ensure drug supply readiness, and engaging specialist consultants to solidify the regulatory pathway with the FDA. Additionally, the capital will maintain and expand Patrys’ intellectual property portfolio, a key asset underpinning its competitive position.
This financing round follows Patrys’ recent efforts to ramp up manufacturing and regulatory engagement for its injectable quetiapine formulation, RLS-2201, which is designed to address a US$2 billion delirium market. The program leverages an accelerated FDA 505(b)(2) pathway and existing safety data to potentially shorten development timelines and reduce costs. These strategic moves were outlined in the company’s earlier update on its injectable quetiapine for delirium market.
Share Structure and Director Participation
Shares issued under the placement will rank equally with existing shares and were issued under the company’s existing ASX Listing Rule capacities. The placement price reflects a 10.8% discount to the recent volume-weighted average price, a common feature in capital raises aimed at securing swift investor commitment.
Investors will also receive one free attaching unlisted option for every four shares subscribed, exercisable at A$0.048 until November 2030, contingent on shareholder approval. Directors have confirmed their intention to participate in the placement to the tune of A$160,000, subject to the same shareholder approval process. This insider participation often signals confidence, though it remains to be approved at an upcoming general meeting.
Costs and Advisory Fees
Templar Corporate acted as sole lead manager for the placement, earning a 6% fee plus GST on funds raised. The company also plans to issue unlisted options to the lead manager and brokers as part of their remuneration, again subject to shareholder approval. These options mirror the terms of those attaching to the placement shares, potentially diluting equity but aligning incentives for capital raising partners.
Settlement of the placement is expected around late April, with the shareholder meeting to approve options and director participation scheduled for early June.
Bottom Line?
Patrys’ latest capital raise provides crucial runway for its injectable quetiapine program, but shareholder approval hurdles and clinical trial execution remain key milestones to monitor.
Questions in the middle?
- Will shareholder approval for director participation and option issuance proceed smoothly?
- How swiftly can Patrys execute its Phase 1A trial given current market and regulatory conditions?
- What impact will the attaching options have on the company’s capital structure and investor returns?